See more : Ikka Holdings Co.,Ltd. (7127.T) Income Statement Analysis – Financial Results
Complete financial analysis of Taysha Gene Therapies, Inc. (TSHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taysha Gene Therapies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- India Tourism Development Corporation Limited (ITDC.NS) Income Statement Analysis – Financial Results
- Sri Trang Gloves (Thailand) Public Company Limited (STGT.BK) Income Statement Analysis – Financial Results
- Bank Millennium S.A. (MIL.WA) Income Statement Analysis – Financial Results
- iA Financial Corporation Inc. (IAF-PB.TO) Income Statement Analysis – Financial Results
- Adani Green Energy Limited (ADANIGREEN.BO) Income Statement Analysis – Financial Results
Taysha Gene Therapies, Inc. (TSHA)
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 15.45M | 2.50M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.49M | 492.00K | 9.00K | 0.00 |
| Gross Profit | 15.45M | 15.00K | -492.00K | -9.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.60% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.78M | 91.17M | 131.94M | 31.89M | 987.00K |
| General & Administrative | 30.05M | 37.36M | 41.32M | 11.11M | 512.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -384.00K |
| SG&A | 30.05M | 37.36M | 41.32M | 11.11M | 128.00K |
| Other Expenses | 1.07M | -18.00K | 0.00 | -17.03M | 0.00 |
| Operating Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
| Cost & Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
| Interest Income | 3.57M | 249.00K | 172.00K | 49.00K | 0.00 |
| Interest Expense | 5.00M | 3.80M | 1.43M | 28.00K | 0.00 |
| Depreciation & Amortization | 1.37M | 2.49M | 492.00K | 9.00K | 4.46M |
| EBITDA | -105.20M | -159.73M | -172.78M | -42.99M | 0.00 |
| EBITDA Ratio | -680.84% | -5,027.82% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.44M | -162.45M | -173.27M | -43.00M | -1.12M |
| Operating Income Ratio | -468.83% | -6,492.69% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -39.13M | -3.57M | -1.26M | -17.01M | 0.00 |
| Income Before Tax | -111.57M | -166.01M | -174.52M | -60.01M | -1.12M |
| Income Before Tax Ratio | -722.06% | -6,635.25% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.57M | 936.00K | -17.01M | -4.46M |
| Net Income | -111.57M | -169.58M | -175.46M | -43.00M | -1.12M |
| Net Income Ratio | -722.06% | -6,777.82% | 0.00% | 0.00% | 0.00% |
| EPS | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| EPS Diluted | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| Weighted Avg Shares Out | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
| Weighted Avg Shares Out (Dil) | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting
Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time Oral presentation by Elsa Rossignol, M.D., FRCP, FAAP, Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrfiend, M.D.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, June 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June...
Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Hayleigh Collins - Director, Head of Corporate Communications and Investor Relations Sean Nolan - Chief Executive Officer and Chairman Sukumar Nagendran...
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.28 per share a year ago.
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
Completed dosing in cohort one (low dose, 5.7x10 14 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x10...
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, May 03, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today...
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
RMAT designation follows FDA's review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today...
Source: https://incomestatements.info
Category: Stock Reports